March Biosciences Elects Peter Olagunju as Chair of Board of Directors
Cell and gene therapy veteran and Board member elected Chair following recent $28.4M Series A financing to advance Phase 2...
Cancer
Immuneering Launches Pancreatic Cancer Advisory Board
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug...
American Oncology Network’s Specialty Pharmacy Achieves ACHC Reaccreditation
American Oncology Network’s Specialty Pharmacy Achieves ACHC Reaccreditation Douglas Braun, PharmD, RPh, CSP, CPh, Vice President of Pharmacy, American Oncology...
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON...
Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on December 19, 2024, it published an...
Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by...
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical...
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12,...
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s MacroglobulinemiaSAN FRANCISCO, Dec. 19,...
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 DiabetesHOUSTON, Dec. 19, 2024 (GLOBE...
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentrationMarlborough, Massachusetts--(Newsfile...
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience...
Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing
Collaboration with Kure.ai to develop ultrafast CAR-T manufacturing process for Hemogenyx Pharmaceuticals' AML Treatment LONDON, UNITED KINGDOM / ACCESSWIRE /...
SuperTruth Acquires imaware and Enables Future Of Reliable AI Data Management and Better Health Outcomes
Real-time information aligns with first-party diagnostics to remediate data decay and reveal pristine insights into medical information NEW YORK, Dec....
The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries
IPIG joins Max's Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on...
Phase 2 Study Initiated to Evaluate Jaguar Health’s Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies -...
Akari Therapeutics Announces Key Leadership Appointments
Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec....
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
Trial will evaluate the safety, pharmacokinetics and pharmacodynamics of RPT1G in adult healthy volunteers in anticipation of their upcoming oncology...
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -...